STOCK TITAN
  1. Home
  2. Sec-filings
  3. TXG
  4. [144] 10x Genomics, Inc. SEC Filing

10x Genomics (NASDAQ: TXG) exec to sell 16,614 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) is the issuer for a planned resale of its common stock under Rule 144 by officer Adam Taich. The notice covers up to 16,614 shares of common stock, with an aggregate market value of $1,081,903.68, to be sold through Morgan Stanley Smith Barney LLC Executive Services, with an approximate sale date of August 24, 2026 on NASDAQ. These shares relate to a Restricted Stock Unit Grant acquired on August 21, 2026 in consideration for services rendered, covering 32,650 shares. Shares outstanding for 10x Genomics were 120,212,296, which is a baseline figure and not the amount being sold.

Positive

  • None.

Negative

  • None.
Shares to be sold 16,614 shares of common stock Maximum number of TXG shares covered by the Rule 144 notice
Aggregate market value $1,081,903.68 Aggregate market value of the 16,614 shares to be sold
Shares outstanding 120,212,296 shares TXG common shares outstanding used as a baseline context figure
RSU grant size 32,650 shares Shares subject to the Restricted Stock Unit Grant acquired August 21, 2026
Approximate sale date August 24, 2026 Planned date for potential Rule 144 sales on NASDAQ
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Unit Grant financial
"Common Stock | 08/21/2026 | Restricted Stock Unit Grant | Issuer"
aggregate market value financial
"Common Stock | ... | 16614 | 1081903.68 | 120212296"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Attorney-in-Fact regulatory
"Signature | Randy Wu, as Attorney-in-Fact for Adam Taich"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing mean for 10x Genomics, Inc. (TXG)?
The filing reports that officer Adam Taich may sell up to 16,614 TXG common shares under Rule 144, with an aggregate market value of $1,081,903.68, through Morgan Stanley Smith Barney LLC Executive Services around August 24, 2026.

How many 10x Genomics (TXG) shares are covered by this Form 144?
The notice covers a potential sale of up to 16,614 shares of TXG common stock with an aggregate market value of $1,081,903.68 as disclosed in the securities information section.

What is the source of the TXG shares in Adam Taich’s Form 144?
The shares relate to a Restricted Stock Unit Grant acquired on August 21, 2026 from the issuer as consideration for services rendered, covering 32,650 shares of 10x Genomics common stock.

When might the TXG shares be sold under this Form 144?
The approximate date of sale disclosed is August 24, 2026, with sales expected to occur on NASDAQ through Morgan Stanley Smith Barney LLC Executive Services.

How many 10x Genomics (TXG) shares were outstanding in this Form 144?
The filing lists 120,212,296 shares of 10x Genomics common stock as outstanding; this figure provides context on company size and is not the number of shares being sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR